Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | LPL | P06858 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ADK | P55263 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10535280 | 0.84 | HRH3 (0.37) | CYP2A6GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL1306384 | 0.83 | GABRA1 (0.38) | TP53GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL4062990 | 0.83 | ACACB (0.43) | ACACBLPLLIPGFFAR1CA2 | |
| SCHEMBL5050178 | 0.81 | CYP2A6 (0.64) | CYP2A6ACACBTP53TAAR1PLAU | |
| SCHEMBL1306505 | 0.81 | APP (0.41) | TP53GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL8228398 | 0.81 | CYP2A6 (0.64) | CYP2A6ACACBTP53TAAR1PLAU | |
| SCHEMBL22722183 | 0.81 | FFAR1 (0.33) | CYP2A6GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL20630692 | 0.81 | TRPA1 (0.36) | CYP2A6GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL1710488 | 0.81 | NOS3 (0.38) | EGLN1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL6517725 | 0.81 | IDO1 (0.43) | CYP2A6GABRA1GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20170164614-A1 | ANTIMICROBIAL MATERIALS AND METHODS | UNIV FLORIDA (US) | 2017-06-15 | — | — | US | disclosed |
| US-9617256-B2 | Antibacterial agents | ACHAOGEN, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9549549-B2 | Antimicrobial materials and methods | STC.UNM (US) | 2017-01-24 | — | — | US | disclosed |
| US-20140242148-A1 | ANTIMICROBIAL MATERIALS AND METHODS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| EP-1303495-B1 | SUBSTITUTED 5-ALKYNYL PYRIMIDINES HAVING NEUROTROPHIC ACTIVITY | KRENITSKY PHARMACEUTICALS INC (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20080142930-A1 | POROUS COMPOSITION OF MATTER, AND METHOD OF MAKING SAME | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2008-06-19 | — | — | US | disclosed |
| US-7368483-B2 | Porous composition of matter, and method of making same | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-7205297-B2 | Substituted 5-alkynyl pyrimidines having neurotrophic activity | KRENITSKY PHARMACEUTICALS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-20040087789-A1 | Substituted 5-alkynyl pyrimidines having neurotrophic activity | MIDCAP FUNDING III, LLC | 2004-05-06 | — | — | US | disclosed |
| EP-1303495-A1 | SUBSTITUTED 5-ALKYNYL PYRIMIDINES HAVING NEUROTROPHIC ACTIVITY | Krenitsky Pharmaceuticals, Inc. (US) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002008205-A1 | SUBSTITUTED 5-ALKYNYL PYRIMIDINES HAVING NEUROTROPHIC ACTIVITY | KRENITSKY PHARMACEUTICALS, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087789-A1 | Substituted 5-alkynyl pyrimidines having neurotrophic activity | BDNF, NTRK2, GAP43 | CYP2A6 3672/4885ACACB 1670/4885TP53 1602/4885 |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | CYP2A6 1425/4885ACACB 1435/4885TP53 350/4885 |
| US-20170164614-A1 | ANTIMICROBIAL MATERIALS AND METHODS | AOC3, OGFOD1, DDT | CYP2A6 946/4885ACACB 4485/4885TP53 4394/4885 |
| US-20140242148-A1 | ANTIMICROBIAL MATERIALS AND METHODS | AOC3, OGFOD1, DDT | CYP2A6 946/4885ACACB 4485/4885TP53 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.